Immunotherapy has changed the standard of care for multiple deadly cancers, including
lung, head and neck, gastric, and some colorectal cancers. However, single-agent …

Pancreatic cancer (PC) remains one of the most lethal malignancies worldwide. Increasing
evidence has confirmed the pivotal role of stromal components in the regulation of …

Pancreatic ductal adenocarcinoma (PDA) is a major cause of cancer-related death, with
limited therapeutic options available. This highlights the need for improved understanding of …

The engineering of new nanomedicines with ability to target and kill or re-educate Tumor
Associated Macrophages (TAMs) stands up as a promising strategy to induce the effective …

Pancreatic cancer is resistant to conventional therapeutic interventions, mainly due to
abundant cancer stromal cells and poor immune cell infiltration. Here, we used a targeted …

The incidence of numerous types of cancer has been increasing over recent years,
representing the second-most frequent cause of death after cardiovascular diseases. Even …

Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy with dire prognosis due
to aggressive biology, lack of effective tools for diagnosis at an early stage, and limited …

The most frequent mutated oncogene family in the history of human cancer is the RAS gene
family, including NRAS, HRAS, and, most importantly, KRAS. A hallmark of pancreatic …

B7-H3 (CD276), a member of the family of immune modulators, orchestrates antitumor
immunity. To date, only small-sized studies have examined the association of B7-H3 …

Pancreatic ductal adenocarcinoma (PDAC) is the 4 th leading cause of cancer-related death
in Western countries with a 5-year survival rate below 5%. One of the hallmarks of this …